Marshall Wace’s IGM Biosciences IGMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-44,287
| Closed | -$49.6K | – | 3107 |
|
|
2025
Q2 | $49.6K | Buy |
+44,287
| New | +$54.1K | ﹤0.01% | 2600 |
|
|
2024
Q3 | – | Sell |
-107,267
| Closed | -$737K | – | 2710 |
|
|
2024
Q2 | $737K | Buy |
107,267
+36,491
| +52% | +$312K | ﹤0.01% | 1812 |
|
|
2024
Q1 | $683K | Buy |
+70,776
| New | +$820K | ﹤0.01% | 1809 |
|
|
2023
Q2 | – | Sell |
-220,319
| Closed | -$3.03M | – | 2682 |
|
|
2023
Q1 | $3.03M | Sell |
220,319
-67,109
| -23% | -$1.39M | 0.01% | 1240 |
|
|
2022
Q4 | $4.89M | Buy |
287,428
+40,739
| +17% | +$815K | 0.01% | 1202 |
|
|
2022
Q3 | $5.61M | Sell |
246,689
-6,046
| -2% | -$122K | 0.01% | 1292 |
|
|
2022
Q2 | $4.56M | Buy |
252,735
+194,679
| +335% | +$3.47M | 0.01% | 1411 |
|
|
2022
Q1 | $1.55M | Buy |
+58,056
| New | +$1.08M | ﹤0.01% | 2207 |
|
|
2021
Q2 | – | Sell |
-26,046
| Closed | -$2M | – | 2835 |
|
|
2021
Q1 | $2M | Buy |
+26,046
| New | +$2.37M | 0.01% | 1328 |
|
|
2020
Q1 | – | Sell |
-4,959
| Closed | -$189K | – | 1837 |
|
|
2019
Q4 | $189K | Buy |
+4,959
| New | +$125K | ﹤0.01% | 1353 |
|
Other funds holding IGMS
Marshall Wace's IGMS Position: Q3 2025 in Review
Marshall Wace sold out of IGM Biosciences (IGMS) in Q3 2025, closing a stake of 44,287 shares — an estimated $49.6K sold.
Marshall Wace first reported a position in IGMS in Q4 2019 and held it in 10 quarters. The position peaked at $5.61M in Q3 2022. 1 fund tracked by Wall St. Rank holds IGMS as of Q3 2025.
- Marshall Wace reported no remaining IGM Biosciences position as of Q3 2025 after selling out during the quarter.
- Marshall Wace sold 44,287 IGM Biosciences shares in Q3 2025, an estimated $49.6K.
- Marshall Wace first reported a position in IGM Biosciences in Q4 2019 and held it in 10 quarters.
- Marshall Wace's IGM Biosciences position peaked at $5.61M in Q3 2022.
- 1 fund tracked by Wall St. Rank held IGM Biosciences as of Q3 2025.
Based on Marshall Wace's 13F filing for Q3 2025, filed 13 Nov 2025.